2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

4:30PM-6:00PM: Abstract Number: 1051

Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design

4:30PM-6:00PM: Abstract Number: 1018

Dietary Intake of Fiber and Risk of Knee Osteoarthritis

Osteoarthritis – Clinical Aspects I: Epidemiology and Progression

4:30PM-6:00PM: Abstract Number: 1048

Differences in Clinical Manifestations of SLE Across Four Racial/Ethnic Groups: The California Lupus Surveillance Project (CLSP)

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design

4:30PM-6:00PM: Abstract Number: 1028

Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 1036

Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects I: Pre-RA and Progression to Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1032

Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis

Rheumatoid Arthritis – Animal Models I

4:30PM-6:00PM: Abstract Number: 1057

Effect of Quantitative Information Concerning Medication Side-Effects on Risk Perception

ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1010

Elucidating the Activation Profile of Systemic Sclerosis Macrophages

Innate Immunity and Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1039

Estimation of the Risk of Developing Rheumatoid Arthritis in High-Risk Subjects : Systematic Review and Meta-Analysis

Rheumatoid Arthritis – Clinical Aspects I: Pre-RA and Progression to Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1053

Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support

ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1037

Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort

Rheumatoid Arthritis – Clinical Aspects I: Pre-RA and Progression to Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 991

Familial Aggregation of Rheumatoid Arthritis in Sarcoidosis: A Register-Based Case-Control Study in Sweden

Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

4:30PM-6:00PM: Abstract Number: 1042

Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment

4:30PM-6:00PM: Abstract Number: 1023

Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 1038

Functional Disability in Patients Presenting with Clinically Suspect Arthralgia and Progression to Clinical Arthritis

Rheumatoid Arthritis – Clinical Aspects I: Pre-RA and Progression to Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].